Here's Why Amgen (AMGN) is a Strong Momentum Stock

Amgen shares rose 9.5% over the past four weeks, while six analysts raised fiscal 2026 earnings estimates in the last 60 days; the Zacks consensus estimate increased $0.72 to $22.94 per share. The stock has a Zacks Rank of #3 (Hold), with B Momentum and VGM scores, and an average earnings surprise of +11.3%. The article also notes headwinds from biosimilar competition and the 2025 loss of patent exclusivity for Prolia and Xgeva.

Analysis

The signal here is estimate-revision momentum, not evidence that Amgen’s underlying growth profile has inflected: a Zacks #3 (Hold) alongside positive revisions makes the article’s “strong momentum” framing less compelling as a standalone buy case. The key second-order test is whether newer products and non-legacy franchises can offset erosion in older products, particularly Prolia and Xgeva, without requiring optimistic assumptions about launch uptake. A rising EPS estimate can coexist with weakening revenue mix if cost actions, timing, or other items support earnings; verify sales and guidance by product before treating revisions as durable.

Near term, the 9.5% four-week share gain raises the risk that a favorable estimate signal is already partly reflected. Over the next 1–3 months, the thesis needs confirmation in reported product-level sales, full-year guidance, and subsequent estimate revisions. Over 6–18 months, biosimilar penetration and replacement-product growth determine whether the portfolio transition sustains earnings. The contrarian risk is that investors overweight near-term estimate momentum and underweight the duration of legacy-drug erosion; conversely, if replacement growth accelerates, the market may be underestimating the transition. No valuation, price, or product-level data are supplied to establish an attractive entry or quantify upside.

Key Decisions for Investors

• Do not chase AMGN solely on the style-score article. For new exposure, wait for a pullback or for reported results to confirm that estimate upgrades are supported by product-level revenue and guidance.
• For existing positions, retain only while forward estimates remain stable or rise and management’s product disclosures show replacement growth offsetting Prolia/Xgeva erosion; reduce if guidance or consensus estimates turn down.
• Track the next earnings report and analyst revisions over the next 1–3 months. Falsification: broad-based estimate cuts, weaker-than-expected replacement-product growth, or faster-than-expected biosimilar-related erosion.
• Before sizing any trade, verify current valuation, the source and durability of the EPS revisions, product-level sales trends, and options-implied volatility; the article does not provide enough to justify a target or options structure.